Computed tomographic images reflect the biologic behavior of small lung adenocarcinoma: They correlate with cell proliferation, microvascularization, cell adhesion, degradation of extracellular matrix, and K-ras mutation  by Dong, Boming et al.
Dong et al General Thoracic SurgeryComputed tomographic images reflect the biologic behavior
of small lung adenocarcinoma: They correlate with cell
proliferation, microvascularization, cell adhesion,
degradation of extracellular matrix, and K-ras mutation
Boming Dong, MD,a Masami Sato, MD,a,b Akira Sakurada, MD,a Motoyasu Sagawa, MD,a,c Chiaki Endo, MD,aShulin Wu, MD,a Sumitaka Yamanaka, MD,a Akira Horii, MD,d and Takashi Kondo, MDa
G
TSFrom the Department of Thoracic Surgery,a
Institute of Development, Aging and Can-
cer, Tohoku University School of Medi-
cine, Sendai, Japan; the Department of
Thoracic Surgery,b Miyagi Cancer Center,
Natori, Japan; the Department of Thoracic
Surgery,c Kanazawa Medical University,
Kanazawa, Japan; and the Department of
Molecular Pathology,d Tohoku University,
Sendai, Japan.
This work was supported in part by the
Grant-in-Aid from the Ministry of Educa-
tion, Culture, Sports, Science, and Technol-
ogy of Japan.
Received for publication March 1, 2005;
revisions received April 29, 2005; accepted
for publication May 16, 2005.
Address for reprints: Masami Sato, MD, De-
partment of Thoracic Surgery, Miyagi Cancer
Center, 47-1, Medeshima-Shiote-aza-No-
dayama, Natori, 981-1293, Miyagi, Japan (E-
mail: m-sato@mcc.pref.miyagi.jp).
J Thorac Cardiovasc Surg 2005;130:733-9
0022-5223/$30.00
Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.05.013Background: We previously reported that the computed tomographic M/L ratio
(area of the tumor in the mediastinal computed tomographic image/area of the tumor
in the lung computed tomographic image) of small peripheral lung adenocarcinoma
is correlated with patient prognosis.
Methods: Immunostaining for p53, bcl-2, Ki-67, vascular endothelial growth factor,
CD34, matrix metalloproteinase 2, matrix metalloproteinase 9, tissue inhibitor of
matrix metalloproteinase 2, and mutation of K-ras was assessed in 131 surgically
resected, primary peripheral lung adenocarcinomas of 30 mm or less in maximum
diameter to clarify the relationship between computed tomographic findings and
biologic activities.
Results: The numbers of patients with high labeling indexes of Ki-67 and high
expression of vascular endothelial growth factor, CD34, matrix metalloproteinase 2,
and matrix metalloproteinase 9 in the solid-type group (computed tomographic M/L
ratio 50%) were significantly higher than those in the faint density–type group
(computed tomographic M/L ratio 50%; P  .04 for Ki-67, P  .03 for vascular
endothelial growth factor, P  .0009 for CD34, P  .001 for matrix metallopro-
teinase 2, and P  .00001 for matrix metalloproteinase 9). The number of patients
with high levels of CD44v6 or tissue inhibitor of matrix metalloproteinase 2 staining
in the faint density–type group was significantly higher than that in the solid-type
group (P  .02 for CD44v6 and P  .01 for tissue inhibitor of matrix metallopro-
teinase 2). Independent variables capable of predicting computed tomographic M/L
ratio included CD34, matrix metalloproteinase 2, matrix metalloproteinase 9, and
tissue inhibitor of matrix metalloproteinase 2 (P  .0093, P  .0003, P  .0027,
and P  .01, respectively; binary logistic regression analysis).
Conclusions: Our results suggest that the computed tomographic image of small
lung adenocarcinoma is correlated with biologic activities and thus provides pos-
sible prognostic information.
Recently, the number of patients with small peripheral lung cancer detectedby means of computed tomographic (CT) scanning has been increasing.Despite the small size of these tumors, some of these patients die of cancer
recurrence. Several factors, including lymph node metastasis, histologic subtype,
size of the central fibrosis, and bronchioloalveolar carcinoma (BAC) component,
have been proved to be of prognostic importance, but few such factors can be
evaluated preoperatively.1-4 In our previous report we reviewed the CT images of
143 patients with primary peripheral lung adenocarcinoma of 30 mm or less in
maximum diameter and classified the patients according to the CT M/L ratio (area
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lung CT image) into a faint density–type group (CT M/L
ratio 50%) and a solid-type group (CT M/L ratio 50%).5
As a result, we found that the 5-year survival of patients
with faint density–type CT images was significantly better
than that of patients with solid-type CT images. Even when
the analyses were limited to the patients without nodal
involvement, there was also a significant difference between
the 2 groups. Multivariate analysis revealed the effect on
prognostic influence of the CT M/L ratio on survival to be
the second highest after that of the N factor.5 Thus preop-
erative classification of patients according to the CT M/L
ratio is a simple but powerful predictor of prognosis for
patients with small-sized lung adenocarcinoma. Adjuvant
treatments, such as chemotherapy and molecular target ther-
apy, are probably necessary for patients with sold-type CT
images. Thus it is important to know the mechanism by
which CT M/L ratio can be used to predict the prognosis for
patients with small-sized lung adenocarcinoma.
The CT M/L ratio might be affected by the pathologic
structure of the tumor. BAC components show low cellular
density because the tumor cells often extend by mimicking
normal alveolar structure. In contrast, fibroblastic prolifer-
ation, formation of a central scar, and neovascularization
might all contribute to an increase in the value of the CT
M/L ratio. None of these factors, however, seems to
uniquely predominate in this CT-pathology-survival corre-
lation. On the other hand, p53, Ki-67, bcl-2, CD44v6,
vascular endothelial growth factor (VEGF), matrix metal-
loproteinase 2 (MMP-2), MMP-9, tissue inhibitor of
MMP-2 (TIMP-2), and K-ras, which were reported to be
prognostic factors of small adenocarcinoma, have some
influence on histologic structure by affecting cell prolifera-
tion, apoptosis, microvascularization, cell adhesion, and the
degradation of the extracellular matrix.6-10 The purpose of
this study was to identify the biologic factors that either
correlated with the CT M/L ratio or predict the prognosis of
small lung adenocarcinoma, so as to clarify the mechanism
of the CT-pathology-survival correlation.
Materials and Methods
Patients, CT Image Analyses, and Tissue Specimen
In this study, we analyzed resected tumor specimens from 131
patients with primary peripheral lung adenocarcinomas with diam-
eters of 30 mm or less in a period between January 1990 and
December 1993. Of the 131 patients, 126 underwent lobectomies,
3 underwent pneumonectomies, and 2 underwent segmental resec-
tions combined with systematic hilar and mediastinal node dissec-
tion. The CT M/L ratios of tumors were calculated as previously
described,5 and all the patients were classified into one of two
groups: a solid-type tumor group and a faint density–type tumor
group. The medical records of all the patients were reviewed for
clinical and pathologic characteristics. The length of survival was
defined as the period from the day of the operation to the last day
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thick sections and two 5-m–thick sections were cut from paraffin
blocks of the resected tumor for immunohistochemical staining
and microdissection, respectively.
Immunohistochemistry
Immunohistologic staining was performed by the streptoavidin-
biotin method (Histofine SAB-PO Kit; Nichirei, Tokyo, Japan),
followed by counterstaining with hematoxylin. For antigen re-
trieval, sections were autoclaved in 10 mmol/L citrate buffer (pH
6.0) before staining. Concentrations of the primary antibodies were
optimized by preliminary examinations. Staining without the pri-
mary antibody was routinely performed as a negative control.
Known immunostaining positive lung adenocarcinoma or squa-
mous cell carcinoma tissue specimens were used as positive con-
trols. The antibodies used in this study were monoclonal p53
antibody (clone DO-7, DAKO, Glostrup, Denmark; diluted 1:50),
monoclonal Bcl-2 antibody (clone 124, DAKO, diluted 1:50),
monoclonal Ki-67 antibody (clone MIB-1, DAKO, diluted 1:50),
monoclonal CD44v6 antibody (clone 2F-10, R&D systems, Min-
neapolis, Minn; diluted 1:250), monoclonal VEGF antibody (clone
R11, IBL, Fujioka, Gunma, Japan; diluted 1:50), monoclonal
CD34 antibody (clone QBEnd 10, DAKO, diluted 1:80), mono-
clonal MMP-2 antibody (clone 8B4, Santa Cruz Biotechnology,
Santa Cruz, Calif; diluted 1:200), monoclonal MMP-9 antibody
(clone 2C3, Santa Cruz Biotechnology, diluted 1:250), and mono-
clonal TIMP-2 antibody (clone 3A4, Santa Cruz Biotechnology,
diluted 1:250). All the slides were reviewed by three physicians
without any knowledge of clinical outcomes or any other clinico-
pathologic data: two of them (M.S. and A.S.) received formal
cytopathologic training. Microscopic evaluation was performed by
counting more than 1000 tumor cells in more than 5 randomly
selected high-power fields (400) from different representative
parts of the tumor. The Ki-67 labeling index (percentage of nu-
clear-stained cells) was defined as high when it exceeded the mean
value (Figure 1, a).6 The p5311 staining was defined as positive
when more than 10% of the tumor cells showed nuclear staining
(Figure 1, b). Bcl-2 (Figure 1, c),6 CD44v6 (Figure 1, d),7 MMP-2
(Figure 1, e),12 MMP-9 (Figure 1, f ),12 and TIMP-2 (Figure 1, g)12
were defined as positive when more than 10% of the tumor cells
showed cytoplasmic staining. For evaluation of VEGF, immuno-
staining was used to determine the percentage of immunoreactive
cells, with the cutoff point for distinguishing specimens with low
from high VEGF expression set at 30% of carcinoma cells (Figure
1, h). Microvessel density (MVD), as measured by CD34 immu-
nostaining, was determined by using a modification of the tech-
nique described by Weidner and colleagues (Figure 1, i).13 The
mean MVD was used as a cutoff point for distinguishing between
tumors with low and high MVDs.
Mutation Analysis of K-ras at Codons 12 and 13
Two hundred or more tumor cells were laser captured on separate
Caps by using a laser capture microdissection microscope (Leica
AS LMD; Leica Microsystems, Tokyo, Japan), according to the
manufacturer’s instructions. DNA was extracted with the QIAamp
DNA Mini Kit (50; QIAGEN, Tokyo, Japan), according to the pro-
tocol provided by the manufacturer. Exon 1 of the K-ras gene was
amplified by the nested polymerase chain reaction (PCR) with the first
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GTCCTGCACCAGTAATATGC-3=) and the nested primer set (5=-
AGGCCTGCTGAAAATGACTG-3= and 5=-CCTCTATTGTTTG-
GATCATATTC-3=), which yielded 205-bp and 125-bp DNA
fragments, respectively, covering codons 12 and 13. PCR was carried
out in a final 25-L reaction mixture containing 4.5 mmol/L Tris-HCl
(pH 8.8), 67 mmol/L (NH4)2SO4, 6.7 mmol/L -mercaptoethanol, 4.5
mol/L ethylenediamine tetraacetic acid, 4.5 mmol/L MgCl2, 0.75
pmol each of deoxyribonucleotide triphosphates, 2.5 pmol of each
primer, and 0.25 units of Taq DNA polymerase.14 The mixture was
heated at 95°C for 5 minutes and then subjected to 40 PCR cycles
(94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds).
The resulting nested PCR products were run on 4% agarose gels,
the 125-bp fragments were isolated, and the DNAs were purified
for sequencing reactions. Nucleotides of both the sense and anti-
sense strands were determined by using the BigDye Terminator
Figure 1. Immunohistochemical staining of serial secti
(a) and p53 (b) proteins and cytoplasmic accumulation
and VEGF (h) proteins are shown in neoplastic cells. (O
cell clusters were considered as a single countable m
is shown in i. (Original magnification 200.)Cycle Sequencing Ready FS Reaction Kit (Applied Biosystems,
The Journal of ThoraciFoster City, Calif) and ABI PRISM 310 Genetic Analyzer (Ap-
plied Biosystems) by means of methods described previously.15
This study was approved by the Ethical Committee of Tohoku
University School of Medicine and conducted according to the
Declaration of Helsinki principles. The appropriate procedure for
obtaining informed consent was followed for all the probable
individuals participating in the study. Permission for investigations
on the old specimens with informed consent that was unavailable
during the period of study was obtained from the Ethical Com-
mittee of Tohoku University School of Medicine on the basis of a
strict evaluation about the essentiality and necessity of the
research.
Statistical Analysis
Survival was calculated by means of the Kaplan-Meier method,
ith various antibodies. Nuclear accumulation of Ki-67
cl-2 (c), CD44v6 (d), MMP-2 (e), MMP-9 (f), TIMP-2 (i),
al magnification 400.) The CD34-stained endothelial
essel, and a tumor area with a high microvessel countons w
of b
rigin
icrovand statistical analysis was performed by the log-rank test. The 2
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logistic regression analysis was used to identify predictors of CT
M/L ratio. The Cox proportional hazards model with a forward
stepwise procedure was applied for multivariate analysis. All sta-
tistical analyses were performed with version 5.0 of the StatView
software package (SAS Institute, Inc, Cary, NC).
Results
Patient characteristics are summarized in Table 1. There
were 53 patients with solid-type tumors and 78 patients with
faint density–type tumors. There were no significant differ-
ences in sex, age distribution, nodal involvement, or histo-
logic grade between the 2 groups. The 5-year survival of
patients with faint density–type images was 81.6%, which
was significantly higher than that of patients with solid-type
CT images (5-year survival, 63.8%; P  .004; Figure 2, a).
Positive staining for Ki-67 and p53 protein was detected
in the nuclei (Figure 1, a and b). In all cases the percentage
of tumor cells positive for Ki-67 protein ranged from 0.6%
to 78.4%, and the mean Ki-67 labeling index was 18.2% 
16.2%. The expressions of bcl-2, CD44v6, MMP-2,
MMP-9, TIMP-2, and VEGF proteins were generally de-
tected in the cytoplasm of tumor cells (Figure 1, c-h). The
mean MVD stained by CD34 (Figure 1, i) for all patients
was 59.2  33.8. The numbers of patients with high label-
ing indexes of Ki-67 and high expressions of VEGF, CD34,
MMP-2, and MMP-9 in the solid-type group were signifi-
cantly greater than those in the faint density–type group
(P  .04 for Ki-67, P  .03 for VEGF, P  .0009 for
CD34, P  .001 for MMP-2, and P  .00001 for MMP-9;
Table 1). The numbers of patients with high levels of
CD44v6 or TIMP-2 staining in the faint density–type group
were significantly greater than those in the solid-type group
(P  .02 for CD44v6 and P  .01 for TIMP-2, Table 1).
There were no significant differences in the expressions of p53
and bcl-2 proteins between the 2 groups (P  .64 for p53 and
P  .10 for bcl-2, Table 1). The 5-year survivals of patients
with high indexes of Ki-67 or low levels of TIMP-2 staining
were poorer than those of patients with low indexes of Ki-67 or
high levels of TIMP-2 staining (P  .026 for Ki-67 and P 
.0005 for TIMP-2; Figure 2, b and c). The expressions of
VEGF, CD34 (MVD), MMP-2, and MMP-9 proteins seem to
be unfavorable prognostic factors (Table 1).
DNA extraction, amplification of K-ras by nested PCR,
and direct sequencing was successful in 95 cases (43 solid
type and 52 faint density type), and K-ras mutations were
found in 18 (19%) tumors, including 17 mutations on codon
12 (9 GGTGly to TGTCys, 4 GGTGly to AGTSer, and 4
GGTGly to GATAsp) and 1 mutation on codon 13
(GGCGly to GACAsp). The frequency of K-ras mutations
in the solid-type group was significantly higher than that in
the faint density–type group (Table 1). The 5-year survival
of patients without a K-ras mutation was 0.78, which was
736 The Journal of Thoracic and Cardiovascular Surgery ● Septsignificantly better than that of those with a K-ras mutation,
which was 0.62 (P  .04; Figure 2, d).
Binary logistic regression analysis revealed the indepen-
dent variables of significance in predicting CT M/L ratio to
be CD34, MMP-9, MMP-2, and TIMP-2 (P  .0093, P 
.0003, P  .0027, and P  .01, respectively). The multi-
variate analysis showed N factor, TIMP-2, Ki-67, and tumor
size to be significant prognostic factors (P  .0001, P 
.0015, P  .030, and P  .048, respectively; Table 2).
Discussion
In this study we found that patients with solid-type tumors had
significantly poorer prognoses than those with faint density–
type tumors (Figure 2). We also observed that a poor prognosis
was associated with high Ki-67 expression and K-ras mutation
(Figure 2). In multivariate analysis, Ki-67 was proved to be an
independent prognostic factor (Table 2). These results were in
good agreement with previous reports.6,11,16-20 In the solid-
type group, the number of patients with high labeling indexes
of Ki-67, as well as K-ras mutation, was significantly higher
than that in the faint density–type group (Table 1). Positive
correlations between K-ras mutation and a high Ki-67 labeling
index, a high MVD, a tumor diameter of greater than 20 mm,
or low expression of CD44v6 (results not shown) suggest that
the K-ras mutation affects biologic behaviors, such as cell
proliferation, microvascularization, and cell adhesion, and thus
the CT M/L ratio in small peripheral lung adenocarcinoma.
Recently, some researchers have reported that increased
levels of VEGF expression and new vessel formation were
associated with the poorer survival of patients with non–
small cell lung cancer.8,9,21-23 In this study, the numbers of
patients with high expression of VEGF and high MVD in
the solid-type group were significantly greater than those in
the faint density–type group (Table 1). In binary logistic
regression analysis, CD34 (MVD) was an independent vari-
able of significance in predicting CT M/L ratio. All these
facts indicated that angiogenesis in the solid-type group was
much more vigorous than that in the faint density–type
group. The newly formed vessels contribute to the increas-
ing CT M/L ratio, as well as to the patient’s poor prognosis.
Molecular target therapy against tumor-related vessel for-
mation might be adequate for patients with solid-type CT
images.
Several recent reports have confirmed that MMP-2 and
MMP-9 might predict the outcome of non–small cell lung
cancer.9,24-26 Kumaki and colleagues27 and Nawrocki and
associates28 have also reported that the expressions of
MMP-2, MMP-9, and TIMP-2 differed between atypical
adenomatous hyperplasia and BAC or between BAC and
invasive adenocarcinoma at the mRNA level or as shown by
immunostaining study. Therefore, we investigated the ex-
pression of these 3 factors and found that the numbers of
patients with high levels of expression of MMP-2 and
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CT findings
No. of patients Solid type* Faint density type† 2 P value 5-y survival
Log-rank test
P value
Sex .91 .40
Male 61 25 36 76.4
Female 70 28 42 72.5
Age (y) 62.9  9.7 62.9  9.6 63.0  9.8 .54 .94
Tumor size .03 .01
20 mm 52 15 37 83.9
20 mm 79 38 41 68.8
Nodal involvement .09 .00001
N0 99 36 63 N vs N N vs N
N1 7 2 5
N2 25 15 10
Histologic grade .015 .02
Well 43 13 30 Well vs moderate  poor Well vs moderate  poor
Moderate 63 29 34
Poor 19 5 14
p stage .08 .00001
I 96 35 61 Stage I vs stage II-IV Stage I vs stage II-IV
II 8 2 6
III 26 16 10
IV 1 1 0
p53 .64 .16
Positive 66 28 38 67.9
Negative 65 25 40 81.3
Ki-67 .04 .03
High 48 25 23 67.7
Low 83 28 55 79.2
Bcl-2 .10 .051
Positive 40 12 28 82.3
Negative 91 41 50 70.9
CD44v6 .02 .056
Positive 80 26 54 79.4
Negative 51 27 24 66.4
VEGF .03 .18
Positive 50 26 24 66.7
Negative 81 27 54 80.4
MVD (CD34) .0009 .23
High 54 31 23 69.9
Low 77 22 55 77.8
MMP-2 .01 .82
Positive 62 34 28 75.0
Negative 69 19 50 74.2
MMP-9 .0001 .058
Positive 93 47 46 69.0
Negative 38 6 32 87.5
TIMP-2 .01 .0005
Positive 90 30 60 83.3
Negative 41 23 18 55.8
K-ras mutations .0003 .04
Mutant 18 15 3 62.2
Wild type 77 28 49 78.4
CT, Computed tomography; VEGF, vascular endothelial growth factor; MVD, microvessel density; MMP-2, matrix metalloproteinase 2; MMP-9, matrix
metalloproteinase 9; TIMP-2, tissue inhibitor of matrix metalloproteinase 2. *Solid type: area of the tumor in mediastinal window/area of the tumor in lung
window of 50% or greater. †Faint density type: area of the tumor in mediastinal window/area of the tumor in lung window of less than 50%.
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MMP-9 or low levels of expression of TIMP-2 in the
solid-type group were significantly greater than those in the
faint density–type group (Table 1). Furthermore, MMP-2,
MMP-9, and TIMP-2 were proved to be the independent
variables of significance in predicting CT M/L ratio, and
TIMP-2 was proved to be a strong independent prognostic
factor of small lung adenocarcinoma both in univariate and
multivariate analysis (Tables 1 and 2 and Figure 2, c). All
these facts suggested that in addition to angiogenesis, deg-
radation of the extracellular matrix was another important
factor that affects the CT M/L ratio, and TIMP-2 might have
an important role in the development and extension of lung
adenocarcinoma. Further research is necessary to explore
the mechanisms of TIMP-2, which affect the CT M/L ratio
and the prognosis of small lung adenocarcinoma.
In conclusion, tumors with solid-type or faint density–
type CT images show significant correlations with factors
such as immunostaining of Ki-67, CD44v6, VEGF, CD34
(MVD), MMP-2, MMP-9, TIMP-2, and K-ras mutation;
Figure 2. Survivals of patients with faint density–type images, negative Ki-67 immunostaining, or positive TIMP-2
immunostaining were significantly greater than those of patients with solid-type images, positive Ki-67 immuno-
staining, or negative TIMP-2 immunostaining (P .004, P .026, and P .0005 in a, b, and c, respectively, by using
the log-rank test). The 5-year survival of patients without K-ras mutation was 0.78 compared with 0.62 for patients
with K-ras mutations (P  .04 in d).
TABLE 2. Multivariate analyses of prognostic factors
Variables
Estimated
coefficient SE P value
Relative risk
(95% CI)
Nodal involvement
(N0 vs N1  2)
2.53 0.36 .0001 0.08 (0.04-0.16)
TIMP-2 1.06 0.33 .0015 2.88 (1.50-5.54)
Ki-67 0.72 0.33 .030 0.49 (0.25-0.93)
Tumor size (20 mm
vs 20 mm)
0.78 0.39 .048 0.46 (0.21-0.99)
SE, Standard error; CI, confidence interval; TIMP-2, tissue inhibitor of
matrix metalloproteinase 2.
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TSseveral factors probably affect the promotion of malignant
potential in solid-type tumors. To the best of our knowl-
edge, our study is the first to evaluate the correlation of
conventional CT images with these biologic factors and to
indicate that the CT M/L ratio might provide some infor-
mation on a tumor’s biologic behaviors and might be a
prognostic tool for evaluating patients with small peripheral
lung adenocarcinoma in the pretreatment period.
We thank Dr Barbara Lee Smith Pierce (University of Mary-
land University College) for editorial work in the preparation of
this article.
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